Orchid Pharma Limited has informed the Exchange in relation to theentering into a Joint Memo of Compromise with DBS Bank India Limited
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Orchid Pharma has entered into a Joint Memo of Compromise with DBS Bank India Limited, indicating a negotiated settlement or restructuring of its outstanding debt obligations with the bank. A Joint Memo of Compromise is typically used when a borrower and lender agree to revised terms to resolve dues, often involving a reduction in principal, interest waiver, or extended repayment schedule. The filing signals that Orchid Pharma and DBS Bank have mutually agreed on terms outside of standard loan repayment. Specific financial details of the compromise — such as the quantum of debt involved or revised terms — have not been disclosed in this filing.
This is broadly positive for Orchid Pharma as it suggests progress in resolving legacy debt issues with DBS Bank, potentially reducing financial burden and clearing a key overhang. However, without disclosed terms, investors should await further details to assess the full financial impact.